Looking for clinico-pathological associations using the expression profile of our series of 50 prostate carcinomas [23], we found two genes (ATF3 and GSTM4) significantly decreased (p = 0.006 and p = 0.015, respectively) and one gene (OR5M3) significantly increased (p = 0.020) in prostate carcinomas with higher Gleason score (GS ≥ 7(4 + 3)) relative to prostate carcinomas with lower Gleason score (GS ≤ 7(3 + 4)) (Figure 7B). The gene discussed is GSTM4; the disease is prostate carcinoma.